Menu Search
Equities

Omeros Corp

3O8:FRA

Omeros Corp

Actions
  • Price (EUR)2.91
  • Today's Change0.074 / 2.61%
  • Shares traded2.00k
  • 1 Year change-42.91%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024 20:55 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

  • Revenue in USD (TTM)0.00
  • Net income in USD-174.92m
  • Incorporated1994
  • Employees198.00
  • Location
    Omeros Corp201 Elliott Avenue WestSEATTLE 98119United StatesUSA
  • Phone+1 (206) 676-5000
  • Fax+1 (206) 676-5005
  • Websitehttps://www.omeros.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.